Reviewing Drug Pathways to Combat Metabolic Fatty Liver Disease
Potential pharmacotherapy pathways in metabolic dysfunction-associated steatotic liver disease
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, is the most common chronic liver disease worldwide, impacting approximately 30% of the adult population and 10% of the pediatric population. It is a significant driver of cirrhosis, hepatocellular carcinoma (liver cancer), and the need for liver transplantation in developed countries, in addition to being an important cardiovascular risk factor. This comprehensive review article aims to synthesize current knowledge and explore potential pharmacotherapy pathways to address the growing burden and complex pathophysiology of MASLD.